Validation of cancer-type-dependent benefit from immune checkpoint blockade in TMB-H tumors identified by the FoundationOne CDx assay.

D J McGrail ,

P G Pilié ,

N U Rashid ,

L Voorwerk ,

M Slagter ,

M Kok ,

E Jonasch ,

M Khasraw ,

A B Heimberger ,

N T Ueno ,

R Ferrarotto ,

J T Chang ,

S-Y Lin

More about this publication

Annals of oncology : official journal of the European Society for Medical Oncology

Volume 33

Issue nr. 11

Pages 1204-1206

Publication date 01-11-2022

Full text links

Publisher website (DOI) 10.1016/j.annonc.2022.07.009

Europe PubMed Central 35926816

Pubmed 35926816